Denali Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Collaboration revenue: | ||||
| Collaboration revenue from customers(1) | $— | $294,123 | $— | $329,264 |
| Total collaboration revenue | — | 294,123 | — | 329,264 |
| Operating expenses: | ||||
| Research and development(2) | 91,399 | 97,520 | 198,415 | 226,336 |
| General and administrative | 25,194 | 26,120 | 50,430 | 53,260 |
| Total operating expenses | 116,593 | 123,640 | 248,845 | 279,596 |
| Gain from divestiture of small molecule programs | — | — | 14,537 | — |
| Income (loss) from operations | (116,593) | 170,483 | (234,308) | 49,668 |
| Interest and other income, net | 17,567 | 12,900 | 33,480 | 23,934 |
| Net income (loss) | (99,026) | 183,383 | (200,828) | 73,602 |
| Other comprehensive income (loss): | ||||
| Net unrealized gain (loss) on marketable securities, net of tax | (1,363) | 1,076 | (3,302) | 5,445 |
| Comprehensive income (loss) | $(100,389) | $184,459 | $(204,130) | $79,047 |
| Net income (loss) per share: | ||||
| Net income (loss) per share, basic | $(0.59) | $1.34 | $(1.26) | $0.54 |
| Net income (loss) per share, diluted | $(0.59) | $1.30 | $(1.26) | $0.52 |
| Weighted-average shares used in calculating: | ||||
| Weighted average number of shares outstanding, basic | 168,831,329 | 137,047,227 | 159,117,759 | 136,787,321 |
| Weighted average number of shares outstanding, diluted | 168,831,329 | 140,930,625 | 159,117,759 | 140,550,226 |
(1)Includes related-party collaboration revenue from customers of $294.1 million and $294.3 million for the three and six months ended June 30, 2023, respectively.
(2)Includes expenses for cost sharing payments due to a related party of $7.0 million and $11.1 million for the three and six months ended June 30, 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.